ATE257152T1 - N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia - Google Patents
N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasiaInfo
- Publication number
- ATE257152T1 ATE257152T1 AT98959050T AT98959050T ATE257152T1 AT E257152 T1 ATE257152 T1 AT E257152T1 AT 98959050 T AT98959050 T AT 98959050T AT 98959050 T AT98959050 T AT 98959050T AT E257152 T1 ATE257152 T1 AT E257152T1
- Authority
- AT
- Austria
- Prior art keywords
- benzyl
- treatment
- indenylaceamide
- neoplasia
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,353 US5948779A (en) | 1997-12-12 | 1997-12-12 | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| US09/206,245 US6066634A (en) | 1997-12-12 | 1998-12-07 | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia |
| PCT/GB1998/003712 WO1999031065A1 (en) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylacetamides derivatives for treating neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257152T1 true ATE257152T1 (de) | 2004-01-15 |
Family
ID=26901185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98959050T ATE257152T1 (de) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6166053A (de) |
| EP (1) | EP1044187B1 (de) |
| JP (1) | JP4307719B2 (de) |
| CN (1) | CN100436418C (de) |
| AT (1) | ATE257152T1 (de) |
| AU (1) | AU752072B2 (de) |
| BR (1) | BR9813540A (de) |
| CA (1) | CA2314339C (de) |
| CZ (1) | CZ298826B6 (de) |
| DE (1) | DE69820908T2 (de) |
| ES (1) | ES2212383T3 (de) |
| HU (1) | HU227153B1 (de) |
| IL (1) | IL136603A0 (de) |
| NO (1) | NO317097B1 (de) |
| NZ (1) | NZ504958A (de) |
| PL (1) | PL196936B1 (de) |
| TR (1) | TR200001687T2 (de) |
| WO (1) | WO1999031065A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
| IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
| AU2001255849B8 (en) * | 2000-04-19 | 2006-04-27 | Lilly Icos, Llc. | PDE-V inhibitors for treatment of Parkinson's Disease |
| DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2002067936A1 (en) * | 2001-02-21 | 2002-09-06 | Cell Pathways, Inc. | Methods for treatment of inflammatory bowel disease |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
| US20030073740A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of lupus erythematosus |
| CN100398522C (zh) * | 2003-08-20 | 2008-07-02 | Irm责任有限公司 | 组织蛋白酶s的抑制剂 |
| US6995622B2 (en) * | 2004-01-09 | 2006-02-07 | Robert Bosh Gmbh | Frequency and/or phase compensated microelectromechanical oscillator |
| JP2008501407A (ja) | 2004-06-02 | 2008-01-24 | メリット ダイアモンド コーポレイション | 装身具のための快適な内側およびその内側を備える装身具 |
| CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
| CN101365461B (zh) * | 2006-01-04 | 2013-07-24 | 南方研究所 | 舒林酸衍生物、其用途和其制备 |
| WO2009022756A1 (ja) * | 2007-08-13 | 2009-02-19 | Katayama Chemical Industries Co., Ltd. | 虚血性疾患の診断及び治療 |
| EP2365746B1 (de) * | 2008-11-04 | 2014-07-16 | Wellstat Therapeutics Corporation | Synthese von (phenylalkyloxy)phenyloxobutansäuren |
| WO2011016737A1 (en) | 2009-08-07 | 2011-02-10 | Auckland Uniservices Limited | Inductive power transfer system |
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| JP7169008B2 (ja) | 2018-04-26 | 2022-11-10 | エーディーティー ファーマシューティカルズ，エルエルシー | 抗がんインデン、インダン、アザインデン、アザインダン、医薬組成物および使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650720B2 (en) * | 1991-03-08 | 1994-06-30 | Fgn, Inc. | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof |
| US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
| CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
| US5948779A (en) * | 1997-12-12 | 1999-09-07 | Cell Pathways, Inc. | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
-
1998
- 1998-12-11 CA CA002314339A patent/CA2314339C/en not_active Expired - Fee Related
- 1998-12-11 AT AT98959050T patent/ATE257152T1/de not_active IP Right Cessation
- 1998-12-11 NZ NZ504958A patent/NZ504958A/xx unknown
- 1998-12-11 EP EP98959050A patent/EP1044187B1/de not_active Expired - Lifetime
- 1998-12-11 TR TR2000/01687T patent/TR200001687T2/xx unknown
- 1998-12-11 DE DE69820908T patent/DE69820908T2/de not_active Expired - Lifetime
- 1998-12-11 CN CNB988118955A patent/CN100436418C/zh not_active Expired - Fee Related
- 1998-12-11 WO PCT/GB1998/003712 patent/WO1999031065A1/en active IP Right Grant
- 1998-12-11 CZ CZ20002157A patent/CZ298826B6/cs not_active IP Right Cessation
- 1998-12-11 AU AU14981/99A patent/AU752072B2/en not_active Ceased
- 1998-12-11 IL IL13660398A patent/IL136603A0/xx active IP Right Grant
- 1998-12-11 ES ES98959050T patent/ES2212383T3/es not_active Expired - Lifetime
- 1998-12-11 PL PL341151A patent/PL196936B1/pl not_active IP Right Cessation
- 1998-12-11 BR BR9813540-6A patent/BR9813540A/pt not_active Application Discontinuation
- 1998-12-11 JP JP2000538992A patent/JP4307719B2/ja not_active Expired - Fee Related
- 1998-12-11 HU HU0100170A patent/HU227153B1/hu not_active IP Right Cessation
-
2000
- 2000-01-24 US US09/490,269 patent/US6166053A/en not_active Expired - Lifetime
- 2000-06-09 NO NO20002972A patent/NO317097B1/no not_active IP Right Cessation
- 2000-12-20 US US09/741,970 patent/US6426349B1/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/206,687 patent/US6610854B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO317097B1 (no) | 2004-08-09 |
| EP1044187A1 (de) | 2000-10-18 |
| CZ298826B6 (cs) | 2008-02-20 |
| AU752072B2 (en) | 2002-09-05 |
| JP4307719B2 (ja) | 2009-08-05 |
| DE69820908T2 (de) | 2004-12-23 |
| WO1999031065A1 (en) | 1999-06-24 |
| HUP0100170A3 (en) | 2001-12-28 |
| EP1044187B1 (de) | 2004-01-02 |
| CZ20002157A3 (cs) | 2000-10-11 |
| US20030009033A1 (en) | 2003-01-09 |
| CA2314339A1 (en) | 1999-06-24 |
| DE69820908D1 (de) | 2004-02-05 |
| NO20002972L (no) | 2000-08-09 |
| JP2002508358A (ja) | 2002-03-19 |
| ES2212383T3 (es) | 2004-07-16 |
| NO20002972D0 (no) | 2000-06-09 |
| CN100436418C (zh) | 2008-11-26 |
| HU227153B1 (en) | 2010-08-30 |
| IL136603A0 (en) | 2001-06-14 |
| BR9813540A (pt) | 2000-10-10 |
| AU1498199A (en) | 1999-07-05 |
| US6166053A (en) | 2000-12-26 |
| PL196936B1 (pl) | 2008-02-29 |
| TR200001687T2 (tr) | 2000-10-23 |
| NZ504958A (en) | 2003-03-28 |
| CN1281436A (zh) | 2001-01-24 |
| CA2314339C (en) | 2009-09-08 |
| PL341151A1 (en) | 2001-03-26 |
| US6426349B1 (en) | 2002-07-30 |
| HUP0100170A1 (hu) | 2001-07-30 |
| US6610854B2 (en) | 2003-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE257152T1 (de) | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ES2074867T3 (es) | Derivados de quinazolina para potenciar la actividad antitumoral. | |
| DK0960127T3 (da) | Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf | |
| ATE222769T1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| TR199901949T2 (xx) | Lemfositik t�m�rler i�in �areler. | |
| DE69921981D1 (de) | ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS | |
| AR016981A2 (es) | Polipeptidos sinteticos | |
| DE69927688D1 (de) | Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs | |
| DE69940980D1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
| EP1198255A4 (de) | Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren | |
| BR9709720A (pt) | Formamidas, acetamidas e propionamidas indezil benzilideno substituìdas | |
| BR9907025B1 (pt) | Polissacarídeos sintéticos e uso dos mesmos | |
| ATE362765T1 (de) | Milchsäurebakterien mit anxiolytischer wirkung, und ihre verwendungen | |
| ATE530640T1 (de) | Integrin-bindungsdomäne der map-kinase | |
| PT971710E (pt) | Utilizacao de queleritrina e radiacao para terapia de tumores | |
| DE69732246D1 (de) | Gewebespezifische expression des retinoblastoma-proteins | |
| DE69935037D1 (de) | Chelatiertes 8-hydroxychinolin zur behandlung von epithelialen verletzungen | |
| ATE238796T1 (de) | Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten | |
| ATE233093T1 (de) | Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren | |
| ATE417926T1 (de) | Zusammensetzungen zur modulierung der länge von telomeren | |
| AU2821000A (en) | Matrix protein compositions for induction of apoptosis | |
| ATE383154T1 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
| GB9723824D0 (en) | Cytostatic agents | |
| ATE292970T1 (de) | Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |